Meta-analysis of single agents in the chemotherapy of NSCLC: what do we want to know?
作者信息
Bahl A, Falk S
出版信息
Br J Cancer. 2001 May 4;84(9):1143-5. doi: 10.1054/bjoc.2000.1740.
Abstract
摘要
相似文献
1
Meta-analysis of single agents in the chemotherapy of NSCLC: what do we want to know?
Br J Cancer. 2001 May 4;84(9):1143-5. doi: 10.1054/bjoc.2000.1740.
2
Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials.
Lung Cancer. 2009 Jan;63(1):50-7. doi: 10.1016/j.lungcan.2008.05.002. Epub 2008 Jun 18.
3
Duration of chemotherapy for metastatic non-small-cell lung cancer: more may be not better.
J Clin Oncol. 2009 Dec 10;27(35):e253; author reply e254. doi: 10.1200/JCO.2009.25.1918. Epub 2009 Nov 2.
4
[Adjuvant chemotherapy in the early stages of non-small cell bronchial cancers].
Rev Pneumol Clin. 2002 Nov;58(5 Pt 2):3S31-2.
5
Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: does cisplatin versus carboplatin make a difference?
J Clin Oncol. 2005 Sep 1;23(25):6276-7; author reply 6277-8. doi: 10.1200/JCO.2005.02.0156.
6
Negative data from lung cancer trial may change practice guidelines, study designs.
J Natl Cancer Inst. 2006 Nov 1;98(21):1518-20. doi: 10.1093/jnci/djj459.
7
Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial.
Eur J Cardiothorac Surg. 2004 Jul;26(1):173-82. doi: 10.1016/j.ejcts.2004.03.041.
8
Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer.
Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):5022s-5026s. doi: 10.1158/1078-0432.CCR-05-9001.
9
Adjuvant chemotherapy for non-small cell lung cancer.
Cancer Invest. 2007 Jun;25(4):217-25. doi: 10.1080/07357900701206281.
10
[Adjuvant chemotherapy in non-small cell lung cancer].
Bull Cancer. 2004 Jan;91(1):63-7.
引用本文的文献
1
Exploring Genetic Variants and Platinum Chemotherapy Response in Indonesian Non-Small Cell Lung Cancer Patients: Insights from rs13181.
Onco Targets Ther. 2024 Sep 20;17:767-776. doi: 10.2147/OTT.S475219. eCollection 2024.
2
Serum miR-27a is a biomarker for the prognosis of non-small cell lung cancer patients receiving chemotherapy.
Transl Cancer Res. 2021 Jul;10(7):3458-3469. doi: 10.21037/tcr-20-3276.
3
Genetic Polymorphisms and the Efficacy of Platinum-Based Chemotherapy: Review.
Pharmgenomics Pers Med. 2020 Oct 8;13:427-444. doi: 10.2147/PGPM.S267625. eCollection 2020.
4
Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors.
Lung Cancer Manag. 2019 May 7;8(2):LMT11. doi: 10.2217/lmt-2018-0016. eCollection 2019 Oct.
5
Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer.
Chin Med J (Engl). 2018 Aug 20;131(16):1904-1908. doi: 10.4103/0366-6999.238141.
6
A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancer.
J Thorac Dis. 2018 Jun;10(6):3575-3584. doi: 10.21037/jtd.2018.06.08.
7
MUC1 overexpression predicts worse survival in patients with non-small cell lung cancer: evidence from an updated meta-analysis.
Oncotarget. 2017 Aug 3;8(52):90315-90326. doi: 10.18632/oncotarget.19861. eCollection 2017 Oct 27.
8
Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy.
Sci Rep. 2017 Sep 6;7(1):10702. doi: 10.1038/s41598-017-10800-5.
9
Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities.
Acta Pharmacol Sin. 2017 Jun;38(6):782-797. doi: 10.1038/aps.2017.34. Epub 2017 May 1.
10
Polymorphism in XRCC1 gene modulates survival and clinical outcomes of advanced North Indian lung cancer patients treated with platinum-based doublet chemotherapy.
Med Oncol. 2017 Apr;34(4):64. doi: 10.1007/s12032-017-0923-4. Epub 2017 Mar 22.
Zotero 插件